These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32663622)

  • 1. Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis.
    Roccatello D; Fenoglio R; Baldovino S; Naretto C; Ferro M; Barreca A; Rossi D; Sciascia S
    Autoimmun Rev; 2020 Sep; 19(9):102622. PubMed ID: 32663622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
    Roccatello D; Fenoglio R; Sciascia S; Naretto C; Rossi D; Ferro M; Barreca A; Malavasi F; Baldovino S
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of renal damage in plasma cell dyscrasias: an overview.
    Merlini G; Pozzi C
    Contrib Nephrol; 2007; 153():66-86. PubMed ID: 17075224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
    Palladini G; Milani P; Malavasi F; Merlini G
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis.
    Godara A; Palladini G
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1145-1159. PubMed ID: 33099430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
    Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
    Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis.
    Del Giudice ML; Galimberti S; Buda G
    Hematol Oncol; 2024 May; 42(3):e3270. PubMed ID: 38590272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary systemic amyloidosis with skin and cardiac involvement: a case report.
    Trajber Horvat A; Trčko K; Jurčić V; Marko PB
    Acta Dermatovenerol Alp Pannonica Adriat; 2018 Mar; 27(1):45-47. PubMed ID: 29589647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies].
    Gödecke V; Schmidt JJ; Bräsen JH; Koenecke C; Haller H
    Internist (Berl); 2019 Jan; 60(1):10-22. PubMed ID: 30635666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
    Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
    Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory.
    Herrera GA
    Ann Diagn Pathol; 2000 Jun; 4(3):174-200. PubMed ID: 10919389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
    Lee H; Tay J; Duggan P; McCulloch S; Neri P; Bahlis NJ; Jimenez-Zepeda VH
    Eur J Haematol; 2021 Mar; 106(3):340-345. PubMed ID: 33197297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
    Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
    Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.
    Sher T; Fenton B; Akhtar A; Gertz MA
    Blood; 2016 Oct; 128(15):1987-1989. PubMed ID: 27543437
    [No Abstract]   [Full Text] [Related]  

  • 16. Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement.
    Godara A; Siddiqui NS; Lee LX; Toskic D; Fogaren T; Varga C; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):184-189. PubMed ID: 31983636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathological atlas of renal diseases: light chain deposition disease.
    Ferrario F; Rastaldi MP
    J Nephrol; 2005; 18(5):499-502. PubMed ID: 16299674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases.
    Buxbaum J; Gallo G
    Hematol Oncol Clin North Am; 1999 Dec; 13(6):1235-48. PubMed ID: 10626147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
    Parrondo RD; Majeed U; Sher T
    Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab for the treatment of AL amyloidosis.
    Sidiqi MH; Gertz MA
    Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.